Integrated leukocyte, oxygen and/or CO
A blood filter device comprising: a housing comprising an outer wall and a first inlet, a first outlet and a second outlet; a membrane which is capable of separating plasma from the blood, wherein the membrane forms an inner chamber; a leukocyte and oxygen and/or carbon dioxide depletion media disposed wherein the inner chamber, the leukocyte and oxygen and/or carbon dioxide depletion media is capable of depleting leukocytes and oxygen and/or carbon dioxide from the blood; an outer chamber disposed between the outer wall and the membrane, wherein the plasma which permeates through the membrane enters the outer chamber and exits the filter device via the first outlet; whereby the blood which has been depleted of oxygen and/or carbon dioxide, leukocytes and plasma exists and filter device via the second outlet.
1. A method for processing blood, comprising:
passing said blood through a blood filter device comprising:
a housing comprising an outer wall, a first inlet, a first outlet and a second outlet;
a membrane which is capable of separating plasma from said blood, wherein said membrane forms at least one inner chamber within said housing and said blood enters said at least one inner chamber of said blood filter device through said first inlet;
a leukocyte and oxygen depletion media disposed within said at least one inner chamber, said leukocyte and oxygen depletion media is capable of depleting leukocytes and oxygen from said blood; and
an outer chamber disposed between said outer wall and said membrane,
separating said plasma from said blood by permeating through said membrane, wherein said plasma enters said outer chamber and exits said housing via said first outlet; and
depleting oxygen, leukocytes and plasma from said blood, whereby oxygen, leukocytes and plasma depleted blood exits said housing via said second outlet as packed red blood cells (pRBCs).
2. The method according to claim 1 , further comprising depleting CO 2 from said blood, and wherein said depletion media is also capable of depleting CO 2 from said blood.
3. The method according to claim 1 , further comprising depleting platelets from said blood, and wherein said depletion media is also capable of depleting platelets from said blood.
4. The method according to claim 1 , further comprising rotating at least one inner chamber relative to said outer chamber.
5. The method according to claim 4 , wherein said rotating creates vortices in said at least one inner chamber.
6. The method according to claim 1 , wherein said pRBCs have an O 2 saturation of 3% or less.
7. The method according to claim 2 , wherein said pRBCs have a pCO 2 of less than 30 mmHg.
8. The method according to claim 1 , wherein said pRBCs have a hematocrit of greater than 35%.
9. The method according to claim 1 , wherein said membrane is at least one membrane formed from at least one material selected from the group consisting of: PVDF rendered hydrophilic, nylon, cellulose esters, polysulfone, polyethersulfone, polypropylene rendered hydrophilic, and polyacrylonitrile.
10. The method according to claim 1 , wherein said membrane is 25 to 250 microns thick.
11. The method according to claim 1 , wherein said membrane has a pore size of less than 2 microns.
12. The method according to claim 1 , wherein said leukocyte and oxygen depletion media comprises a macroporous structure comprising an oxygen sorbent material and a leukoreduction material.
13. The method according to claim 12 , wherein said macroporous structure further comprises a CO 2 sorbent material, and wherein said CO 2 sorbent material is a metal oxide or metal hydroxide.
14. The method according to claim 12 , wherein said macroporous structure is an oxygen sorbent material coated with a biocompatible leukocyte binding surface chemistry.
15. The method according to claim 12 , wherein said macroporous structure has a feature selected from the group consisting of a mean flow pore of between 10 and 30 microns, a surface area of at least 5×10 3 cm 2 /gram media, and a combination thereof.
16. The method according to claim 12 , wherein said macroporous structure comprises a structure selected from the group consisting of:
a. microspheres coated with a biocompatible leukocyte binding surface chemistry, wherein said microspheres are then incorporated into a leukoreduction filler material;
b. layers of microspheres;
c. one or more fibers; and
d. one or more fibers formed into a filter structure.
17. The method according to claim 16 , wherein said one or more fibers are formed from at least one material selected from the group consisting of poly(ethylene methacrylate cyclohexenyl methylacrylate), a polyolefin, a polyamide, a polyester, ethylene/vinyl cyclohexene copolymer (EVCH), and combinations thereof.
18. The method according to claim 16 , wherein said one or more fibers comprise fibers selected from the group consisting of:
a. a leukoreduction fiber and an oxygen sorbent fiber;
b. a combined leukoreduction binding and an oxygen depletion fiber;
c. a CO 2 depletion fiber;
d. an oxygen sorbent fiber surrounded by biocompatible leukocyte binding fibers; and
e. an oxygen sorbent fiber and a carbon dioxide sorbent fiber surrounded by biocompatible leukocyte binding fibers.
19. The method according to claim 12 , wherein said leukoreduction material is at least one polymer selected from the group consisting of: polyolefins, polyamides, polyesters, and other polymers which may be blended with an oxygen scavenger the polymer form and then spun into fibers.
20. The method according to claim 1 , wherein said passing is performed at a flow rate of at least 3 ml/minute.